top of page
Assoc. Prof. Eda Tanrıkulu Şimşek, M.D

Assoc. Prof. Eda Tanrıkulu Şimşek, M.D

Medical Oncology

BIOGRAPHY


After graduating from Ankara University Faculty of Medicine in 2005, she completed her compulsory service in Kars in 2006. Between 2007-2012, she completed his internal medicine residency training at Istanbul University Cerrahpasa Faculty of Medicine. In 2013, she started her medical oncology education at Marmara University Faculty of Medicine, Department of Medical Oncology, ranking 3rd in Turkey in the minor specialization exam. She completed her medical oncology specialization training in 2017 and worked as a medical oncology specialist and medical oncology unit manager at Haydarpasa Numune Training and Research Hospital between 2018-2021. Mrs. Tanrıkulu Simsek, who has served as an assistant and principal researcher in many international clinical studies in the field of medical oncology, started to work as a Medical Oncology Specialist at Anadolu Medical Center as of December 2021.


EDUCATION


2005 Ankara University Faculty of Medicine, Ankara

2012 Internal Medicine Specialist, Istanbul University Cerrahpasa Faculty of Medicine 2017 Medical Oncology specialist, Marmara University Faculty of Medicine


FOCUS OF INTEREST


Breast cancer

Urological cancers

Colon and rectum cancers

Malign melanoma

Personalized treatments


PROFESSIONAL MEMBERSHIPS


European Society of Medical Oncology (ESMO)

American Society of Medical Oncolgy (ASCO)

Turkish Medical Oncology Society (TTOD)


AWARDS


2013 Turkish Hematology Association, Hematology Thesis Award


COURSES ATTENDED


Turkish-Chinese Cooperation Project,Colorectal Cancer Exchange Program, Shanghai, China. 2014

Oxford University Radcliffe Department of Medicine, Metastatic Colorectal Cancer Preceptorship, Oxford, England, 2015

The CHRISTIE Preceptorship on Lung Cancer- ESMO, Manchester, England, 2016

Roche

European Melanoma Experience Exchange:focus on Therapy, Essen, Germany(Online), 2020


PUBLICATIONS


1- Simsek ET, Coban E, Atag E, Gungor S, Sari M, Gurleyik G. The Role of FDG PET/CT to Evaluation of Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer. J Coll Physicians Surg Pak. 2021 Jul;30(7):792-797.


2- Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, Ferhanoglu B, Aydin Y, Tuzuner N, Soysal T. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. J Clin Pathol. 2016 Sep;69(9):810-6.


3- Tanrikulu Simsek E, Dane F. Nutrition in Cancer Patients Who Have Problems in Oral Taking. Türkiye Klinikleri Tıbbi Onkoloji Kanser ve Beslenme Özel sayısı. Turkiye Klinikleri J Med Oncol-Special Topics. 2016;9(3):58-64.


4- Tanrikulu Simsek E, Dane F. Primary Central Nervous System Lymphomas: Diagnosis, Staging and Systemic Treatment. Eriskin Santral Sinir Sistemi Tümörleri Özel sayısı. Turkiye Klinikleri J Med Oncol-Special Topics. 2019. p.78-83.


5- Tanrıkulu Simsek E, Besiroglu M, Aktas B, Koca S, Halil S, Alan Ö, Hasanov R, Akgül Babacan N, Öztürk MA, Kaya S, Ozdogan OC, Dane F, Yumuk PF. Can we Restart Vemurafenib after Severe Hepatotoxicity? A Case Report. J J Gastro Hepato. 2015, 2(4): 025.


6- Simsek ET, Coban E, Atag E, Gungor S, Aker F, Sari M. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients Planning Neoadjuvant Treatment. J Coll Physicians Surg Pak. 2021


7- Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Chordoma: a case series and review of the literature. J Med Case Rep. 2018 Aug 27;12(1):239.


8- Alan O, Telli TA, Ercelep O, Hasanov R, Simsek ET, Mutis A, Ones T, Kaya H, Yumuk PF. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. Curr Probl Cancer. 2019 Aug;43(4):308-311


9- Kaya S, Aktas B, Tanrikulu Simsek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F. Changes in 18F- FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone- positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198.


10- Gurleyik G, Aksu SA, Aker F, Tekyol KK, Tanrikulu E, Gurleyik E. Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy. Ann Surg Treat Res. 2021 Jun;100(6):305-312.


11- Kaytaz Tekyol K, Gurleyik G, Aktas A, Aker F, Tanrikulu E, Tekyol D. Pathological Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: The Relationship Between Inflammatory Biomarkers and Molecular Subtypes. Cureus. 2021 Apr 30;13(4):e14774. doi: 10.7759/cureus.14774. PMID: 34094739; PMCID: PMC8164848.


12- Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrıkulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Arıbal ME, Kuzan B, Dane F, Yumuk PF. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutr Cancer. 2021;73(2):230- 238.


13- Demircan NC, Dane F, Ozturk MA, Babacan NA, Besiroglu M, Kaya S, Ercelep O, Tanrikulu E, Halil S, Koca S, Alan O, Hasanov R, Yumuk PF. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. J BUON. 2019 Jul-Aug;24(4):1494-1500.


14- Dulundu E, Attaallah W, Tilki M, Yegen C, Coskun S, Coskun M, Erdim A, Tanrikulu E, Yardimci S, Gunal O. Simultaneous resection for colorectal cancer with synchronous liver metastases is a safe procedure: Outcomes at a single center in Turkey. Biosci Trends. 2017 May 23;11(2):235-242.


15- Aydin D, Sendur MA, Kefeli U, Umut Unal O, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Bala Ustaalioglu B, Sener Dede D, Esbag O, Inal A, Bilir C, Bilici A, Harputlu H, Berk V, Sevinc A, Yildirim Ozdemir N, Yildirim E, Sonkaya A, Ali Ustaoglu M, Gumus M. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO). J BUON. 2016 Sept-Oct;21(5):1242-1249.


16- Demirci NS, Aksoy S, Özdemir NY, Erdem GU, Ozcelik M, Tanrikulu E, Eren T, Bozkaya Y, Sahin S, Basol F, Aslan SA, Zengin N, Güllü İ. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study. Curr Med Res Opin. 2017 Mar;33(3):401-407.


17- Aydin D, Sendur MA, Kefeli U, Unal OU, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Ustaalioglu BB, Uysal M, Esbag O, Yazilitas D, Tanrıverdi O, Bilici A, Arpaci E, Berk V, Yetisyigit T, Ozdemir NY, Oztop I, Alacacioglu A, Aydin O, Ozcelik M, Yildirim E, Dinc N, Gumus M. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection. Clin Colorectal Cancer. 2017 Sep;16(3):220-227.


18- Arı MC, Büyüktas D, Eskazan AE, Ongören Aydın S, Tanrıkulu E, Baslar Z, Buyru AN, Ferhanoglu B, Aydın Y, Tüzüner N, Soysal T. The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Turk J Haematol. 2012 Sep;29(3):242-7.


19- Ugurlu S, Caglar E, Yesim TE, Tanrikulu E, Can G, Kadioglu P. Evaluation of thyroid nodules in Turkish population. Intern Med. 2008;47(4):205-9.


20- Ercelep O, Alan O, Telli TA, Tuylu TB, Arıkan R, Demircan NC, Simsek ET, Babacan NA, Kaya S, Dane F, Bozkurtlar E, Ones T, Lacin T, Yumuk PF. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori. 2021 Jun;107(3):231-237.


21- Seyahi E, Baskurt M, Melikoglu M, Akman C, Olgun DC, Simsek E, Hamuryudan V, Kucukoglu S, Yazici H. The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. Respir Med. 2011 Nov;105(11):1739-47.


22- Ercelep Ö, Akın Telli T, Alan Ö, Hasanov R, Tanrıkulu Simsek E, Akgül Babacan N, Kaya S, Kaya H, Dane F, Yumuk PF. Smokers having activating egfr mutant non-small cell lung cancer might Benefit from EGFR-TKI Treatment – Single-Center Experience. Turk J Oncol 2020;35(3):334–9.


23- Bavunoglu I, Balta M, Tanrıkulu E, Türkmen Z, Ikizceli I. Unexpected Diagnosis in the Metropolis: Organophosphate Poisoning. JAEMCR 2012; 3(2): 52-5.


24- Oven B, Celik S, Okten IN, Tanrıkulu E, Aliyev A, Seker M. Approachment to the Brain Metastasis without Extracranial Metastasis of the HER2 Positive Metastatic Breast Cancer. Volume 3(6): 2-6. 2020.


25- Alan Ö, Ercelep Ö, Akın Telli T, Tanrıkulu Simsek E, Hasanov R, Basoglu T, Öztürk MA, Kaya S, Akgül Babacan NI Laçin T, Bozkurtlar E, Dane F, Yumuk PF. Opere Erken Evre Akciger Kanseri Hastalarında Prognostik Faktörler Retrospektif Tek Merkez Sonuçları. Namık Kemal Tıp Dergisi 2020; 8(3): 376 - 382.

LookForMed Health Tourism 2024

bottom of page